Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study
Background This study investigated the effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on patients with stage 4 cardiovascular–kidney–metabolic syndrome over 1 year. Methods Data from patients with stage 4 cardiovascular–kidney–metabolic syndrome hospitalized at Civil Aviation General...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.124.040382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233320613773312 |
|---|---|
| author | Tao Liu Zeyuan Fan Yuntao Li Bing Xiao Chang He |
| author_facet | Tao Liu Zeyuan Fan Yuntao Li Bing Xiao Chang He |
| author_sort | Tao Liu |
| collection | DOAJ |
| description | Background This study investigated the effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on patients with stage 4 cardiovascular–kidney–metabolic syndrome over 1 year. Methods Data from patients with stage 4 cardiovascular–kidney–metabolic syndrome hospitalized at Civil Aviation General Hospital from March 2021 to September 2023 were collected. Patients were classified into the SGLT2i group and the control group on the basis of SGLT2i exposure. A propensity score–matched model established a well‐balanced comparison between the groups. The initial occurrence of major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs) and all‐cause death within 1 year were assessed. Results A total of 3657 patients were included, resulting in 812 matched pairs. The SGLT2i group exhibited significant reductions in MACEs, MAKEs, and all‐cause death compared with the control group. Based on adjusted Cox regression, those receiving SGLT2is had a 27.4% lower hazard for MACEs, driven primarily by a 12.4% lower hazard for cardiovascular death and 32.7% lower hazard for heart failure readmission. SGLT2i use reduced the hazard for MAKEs by 11.5%, primarily due to a 19.7% reduction in the hazard for worsen kidney function. All‐cause mortality hazard decreased by 11.3%. Subgroup analyses confirmed consistent cardiovascular and renal benefits of SGLT2is. Further sensitivity analyses supported the robustness of the results. Conclusions SGLT2i use in patients with stage 4 cardiovascular–kidney–metabolic syndrome was associated with reduced hazards of MACEs, MAKEs, and all‐cause death, supporting the cardiovascular and renal benefits in this population. |
| format | Article |
| id | doaj-art-53973e54e0d54d84bbff2041e5d88422 |
| institution | Kabale University |
| issn | 2047-9980 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-53973e54e0d54d84bbff2041e5d884222025-08-20T07:24:54ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-08-01141610.1161/JAHA.124.040382Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched StudyTao Liu0Zeyuan Fan1Yuntao Li2Bing Xiao3Chang He4Department of Coronary Heart Disease Civil Aviation General Hospital Beijing ChinaDepartment of Coronary Heart Disease Civil Aviation General Hospital Beijing ChinaDepartment of Coronary Heart Disease Civil Aviation General Hospital Beijing ChinaDepartment of Coronary Heart Disease Civil Aviation General Hospital Beijing ChinaDepartment of Coronary Heart Disease Civil Aviation General Hospital Beijing ChinaBackground This study investigated the effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on patients with stage 4 cardiovascular–kidney–metabolic syndrome over 1 year. Methods Data from patients with stage 4 cardiovascular–kidney–metabolic syndrome hospitalized at Civil Aviation General Hospital from March 2021 to September 2023 were collected. Patients were classified into the SGLT2i group and the control group on the basis of SGLT2i exposure. A propensity score–matched model established a well‐balanced comparison between the groups. The initial occurrence of major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs) and all‐cause death within 1 year were assessed. Results A total of 3657 patients were included, resulting in 812 matched pairs. The SGLT2i group exhibited significant reductions in MACEs, MAKEs, and all‐cause death compared with the control group. Based on adjusted Cox regression, those receiving SGLT2is had a 27.4% lower hazard for MACEs, driven primarily by a 12.4% lower hazard for cardiovascular death and 32.7% lower hazard for heart failure readmission. SGLT2i use reduced the hazard for MAKEs by 11.5%, primarily due to a 19.7% reduction in the hazard for worsen kidney function. All‐cause mortality hazard decreased by 11.3%. Subgroup analyses confirmed consistent cardiovascular and renal benefits of SGLT2is. Further sensitivity analyses supported the robustness of the results. Conclusions SGLT2i use in patients with stage 4 cardiovascular–kidney–metabolic syndrome was associated with reduced hazards of MACEs, MAKEs, and all‐cause death, supporting the cardiovascular and renal benefits in this population.https://www.ahajournals.org/doi/10.1161/JAHA.124.040382cardiovascular–kidney–metabolic syndromemajor adverse cardiovascular eventsmajor adverse kidney eventspropensity score–matchedsodium–glucose cotransporter 2 inhibitors |
| spellingShingle | Tao Liu Zeyuan Fan Yuntao Li Bing Xiao Chang He Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease cardiovascular–kidney–metabolic syndrome major adverse cardiovascular events major adverse kidney events propensity score–matched sodium–glucose cotransporter 2 inhibitors |
| title | Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study |
| title_full | Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study |
| title_fullStr | Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study |
| title_full_unstemmed | Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study |
| title_short | Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study |
| title_sort | effects of sodium glucose cotransporter 2 inhibitors on stage 4 cardiovascular kidney metabolic syndrome a propensity score matched study |
| topic | cardiovascular–kidney–metabolic syndrome major adverse cardiovascular events major adverse kidney events propensity score–matched sodium–glucose cotransporter 2 inhibitors |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.124.040382 |
| work_keys_str_mv | AT taoliu effectsofsodiumglucosecotransporter2inhibitorsonstage4cardiovascularkidneymetabolicsyndromeapropensityscorematchedstudy AT zeyuanfan effectsofsodiumglucosecotransporter2inhibitorsonstage4cardiovascularkidneymetabolicsyndromeapropensityscorematchedstudy AT yuntaoli effectsofsodiumglucosecotransporter2inhibitorsonstage4cardiovascularkidneymetabolicsyndromeapropensityscorematchedstudy AT bingxiao effectsofsodiumglucosecotransporter2inhibitorsonstage4cardiovascularkidneymetabolicsyndromeapropensityscorematchedstudy AT changhe effectsofsodiumglucosecotransporter2inhibitorsonstage4cardiovascularkidneymetabolicsyndromeapropensityscorematchedstudy |